Loading...
•
Dec 31, 2021
Eagle Q4 2021 Earnings Report
Reported a net loss and an adjusted non-GAAP net income for Q4 2021.
Key Takeaways
Eagle Pharmaceuticals reported Q4 2021 financial results with a net loss of $(0.48) per share and adjusted non-GAAP net income of $0.85 per diluted share. The company launched two new products, vasopressin and PEMFEXY, and anticipates a strong Q1 2022.
Q4 2021 net loss was $(0.48) per basic and diluted share.
Adjusted non-GAAP net income was $0.87 per basic and $0.85 per diluted share.
Started shipping vasopressin with 180 days of marketing exclusivity.
Launched PEMFEXY, a branded alternative to ALIMTA.
Eagle
Eagle
Eagle Revenue by Segment
Revenue by Segment
BELRAPZO product sales Revenue
CapyFin.comRYANODEX product sales Revenue
CapyFin.com Forward Guidance
The company anticipates Q1 2022 revenue to be in the range of $120 million - $130 million and adjusted non-GAAP earnings per share in the range of $3.80 - $4.10.
Revenue & Expenses
Visualization of income flow from segment revenue to net income